Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients ...

This randomized phase III trial was performed to compare the 3-monthly depot LHRH agonist leuprorelin acetate (LAD-3M; n = 299) and chemotherapy with cyclophosphamide, methotrexate, and fluorouracil ...

August 26, 2010 — Leuprorelin does not appear to improve swallowing function in patients with spinal and bulbar muscular atrophy (SBMA), although a subgroup analysis suggests that it might benefit ...

European safety experts are to begin a review of leuprorelin-containing medicines, commonly used in breast and prostate cancer and as a contraceptive. The European Medicines Agency’s Pharmacovigilance ...

The European Medicine Agency's (EMA's) safety committee has recommended that new measures be taken to avoid handling errors in the preparation and administration of leuprorelin depot medicines. A ...

Scottish Medicines Consortium accepts PROSTAP® SR DCS & PROSTAP® 3 DCS (leuprorelin acetate) to treat early and advanced breast cancer[1] [2] London, UK – 8 February 2021, Takeda is pleased to ...

Daewoong Pharmaceutical and Dongkook Pharmaceutical, which have led the domestic market for precocious puberty treatments containing leuprorelin, are now subject to a re-evaluation of their generics.

Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Leuprorelin Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. According to the market ...

Details concerning the Leuprorelin medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and injections.